Enliven Therapeutics (ELVN) Operating Expenses (2019 - 2026)

Enliven Therapeutics has disclosed Operating Expenses across 8 years of filings, most recently posting $27.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $27.8 million, down 12.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.8 million (up 5.01% YoY), and the FY2025 annual result was $119.7 million, up 14.45% from the prior year.
• Operating Expenses came in at $27.8 million for Q1 2026 at Enliven Therapeutics, down from $34.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $34.3 million in Q4 2025 to a low of $8.7 million in Q1 2022.
• The 5-year median for Operating Expenses is $24.6 million (2024), against an average of $22.0 million.
• Across the five-year window, Operating Expenses slumped 31.54% in 2022 and surged 123.64% in 2023, its largest moves.
• Enliven Therapeutics' Operating Expenses stood at $10.2 million in 2022, then jumped by 123.64% to $22.7 million in 2023, then grew by 18.33% to $26.9 million in 2024, then grew by 27.47% to $34.3 million in 2025, then decreased by 18.85% to $27.8 million in 2026.
• The last three Operating Expenses figures came in at $27.8 million (Q1 2026), $34.3 million (Q4 2025), and $25.1 million (Q3 2025), per Business Quant data.